59 related articles for article (PubMed ID: 14965710)
1. Oncogenes, granules and breast cancer: what has c-myc to do with apocrine changes?
Schmitt FC; Reis-Filho JS
Breast; 2002 Dec; 11(6):463-5. PubMed ID: 14965710
[TBL] [Abstract][Full Text] [Related]
2. C-myc oncoprotein expression and gene amplification in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
Selim AG; El-Ayat G; Naase M; Wells CA
Breast; 2002 Dec; 11(6):466-72. PubMed ID: 14965711
[TBL] [Abstract][Full Text] [Related]
3. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
Selim AG; El-Ayat G; Wells CA
Virchows Arch; 2002 Nov; 441(5):449-55. PubMed ID: 12447674
[TBL] [Abstract][Full Text] [Related]
4. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
Elayat G; Selim AG; Wells CA
Ann Diagn Pathol; 2010 Feb; 14(1):1-7. PubMed ID: 20123450
[TBL] [Abstract][Full Text] [Related]
5. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
[TBL] [Abstract][Full Text] [Related]
6. MYC amplification and TERT expression in breast tumor progression.
Bodvarsdóttir SK; Steinarsdóttir M; Hilmarsdóttir H; Jónasson JG; Eyfjörd JE
Cancer Genet Cytogenet; 2007 Jul; 176(2):93-9. PubMed ID: 17656250
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle alterations and their relationship to proliferation in apocrine adenosis of the breast.
Elayat G; Selim AG; Wells CA
Histopathology; 2009 Feb; 54(3):348-54. PubMed ID: 19236511
[TBL] [Abstract][Full Text] [Related]
8. PEG10 is a c-MYC target gene in cancer cells.
Li CM; Margolin AA; Salas M; Memeo L; Mansukhani M; Hibshoosh H; Szabolcs M; Klinakis A; Tycko B
Cancer Res; 2006 Jan; 66(2):665-72. PubMed ID: 16423995
[TBL] [Abstract][Full Text] [Related]
9. The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma.
Corzo C; Corominas JM; Tusquets I; Salido M; Bellet M; Fabregat X; Serrano S; Solé F
Cancer Genet Cytogenet; 2006 Mar; 165(2):151-6. PubMed ID: 16527609
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of c-Myc in primary central nervous system lymphoma of Thais.
Assanasen T; Shuangshoti S; Nilyai S; Wannakrairot P; Ruangvejvorachai P; Sawatdee R; Sangprakarn S
J Med Assoc Thai; 2006 Sep; 89 Suppl 3():S40-6. PubMed ID: 17718267
[TBL] [Abstract][Full Text] [Related]
11. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
[TBL] [Abstract][Full Text] [Related]
12. Tumour angiogenesis and C-myc expression in breast carcinomas.
Shanmugham R; Gopalan R; Shanthi P; Krishnan KB
Indian J Pathol Microbiol; 2004 Jul; 47(3):340-2. PubMed ID: 16295419
[TBL] [Abstract][Full Text] [Related]
13. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers.
Park K; Kwak K; Kim J; Lim S; Han S
Hum Pathol; 2005 Jun; 36(6):634-9. PubMed ID: 16021569
[TBL] [Abstract][Full Text] [Related]
14. Growth factor-dependent regulation of survivin by c-myc in human breast cancer.
Cosgrave N; Hill AD; Young LS
J Mol Endocrinol; 2006 Dec; 37(3):377-90. PubMed ID: 17170079
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow stroma influences transforming growth factor-beta production in breast cancer cells to regulate c-myc activation of the preprotachykinin-I gene in breast cancer cells.
Oh HS; Moharita A; Potian JG; Whitehead IP; Livingston JC; Castro TA; Patel PS; Rameshwar P
Cancer Res; 2004 Sep; 64(17):6327-36. PubMed ID: 15342422
[TBL] [Abstract][Full Text] [Related]
16. Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer.
Varga Z; Zhao J; Ohlschlegel C; Odermatt B; Heitz PU
Histopathology; 2004 Apr; 44(4):332-8. PubMed ID: 15049898
[TBL] [Abstract][Full Text] [Related]
17. Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.
Miura S; Nakashima M; Ito M; Kondo H; Meirmanov S; Hayashi T; Soda M; Matsuo T; Sekine I
Cancer; 2008 May; 112(10):2143-51. PubMed ID: 18348306
[TBL] [Abstract][Full Text] [Related]
18. c-myc amplifications in primary breast carcinomas and their local recurrences.
Aulmann S; Adler N; Rom J; Helmchen B; Schirmacher P; Sinn HP
J Clin Pathol; 2006 Apr; 59(4):424-8. PubMed ID: 16497871
[TBL] [Abstract][Full Text] [Related]
19. c -MYC amplification and expression in astrocytic tumors.
Faria MH; Khayat AS; Burbano RR; Rabenhorst SH
Acta Neuropathol; 2008 Jul; 116(1):87-95. PubMed ID: 18369647
[TBL] [Abstract][Full Text] [Related]
20. Frequent amplifications and deletions of G1/S-phase transition genes, CCND1 and MYC in early breast cancers: a potential role in G1/S escape.
Jensen LB; Bartlett JM; Witton CJ; Kirkegaard T; Brown S; Müller S; Campbell F; Cooke TG; Nielsen KV
Cancer Biomark; 2009; 5(1):41-9. PubMed ID: 19242061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
